Corium International Inc to Post FY2018 Earnings of ($1.50) Per Share, Cantor Fitzgerald Forecasts (CORI)

Corium International Inc (NASDAQ:CORI) – Cantor Fitzgerald reduced their FY2018 earnings per share (EPS) estimates for Corium International in a research note issued on Tuesday, May 22nd. Cantor Fitzgerald analyst W. Tanner now expects that the biopharmaceutical company will earn ($1.50) per share for the year, down from their previous estimate of ($1.32). Cantor Fitzgerald currently has a “Buy” rating and a $14.00 target price on the stock. Cantor Fitzgerald also issued estimates for Corium International’s FY2019 earnings at ($1.09) EPS.

Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). The company had revenue of $10.06 million during the quarter, compared to the consensus estimate of $7.07 million. Corium International had a negative return on equity of 273.01% and a negative net margin of 156.05%.

Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Corium International from a “hold” rating to a “sell” rating in a research note on Thursday, May 17th. BidaskClub lowered shares of Corium International from a “sell” rating to a “strong sell” rating in a research note on Tuesday. HC Wainwright set a $14.00 price objective on shares of Corium International and gave the company a “buy” rating in a research note on Tuesday, May 15th. Finally, ValuEngine upgraded shares of Corium International from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $13.00.

NASDAQ:CORI opened at $8.43 on Thursday. The company has a current ratio of 8.11, a quick ratio of 7.95 and a debt-to-equity ratio of 1.89. The company has a market capitalization of $296.35 million, a P/E ratio of -5.14 and a beta of 1.61. Corium International has a 12 month low of $6.77 and a 12 month high of $13.93.

A number of institutional investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its stake in Corium International by 115.3% in the 1st quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock valued at $23,618,000 after buying an additional 1,102,910 shares in the last quarter. BlackRock Inc. grew its stake in Corium International by 11.9% in the 1st quarter. BlackRock Inc. now owns 1,880,505 shares of the biopharmaceutical company’s stock valued at $21,569,000 after buying an additional 200,690 shares in the last quarter. RTW Investments LP grew its stake in Corium International by 1.4% in the 4th quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock valued at $16,334,000 after buying an additional 24,174 shares in the last quarter. Tamarack Advisers LP grew its stake in Corium International by 9.4% in the 1st quarter. Tamarack Advisers LP now owns 1,105,000 shares of the biopharmaceutical company’s stock valued at $12,674,000 after buying an additional 95,000 shares in the last quarter. Finally, Opaleye Management Inc. grew its stake in Corium International by 15.2% in the 4th quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock valued at $10,186,000 after buying an additional 140,000 shares in the last quarter. Institutional investors and hedge funds own 95.13% of the company’s stock.

Corium International Company Profile

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Earnings History and Estimates for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply